Targeted Importation: A Drug Pricing Mechanism For 'Predatory Actors' And An A-Pauling HHS Confirmation Dilemma
For those old drug re-pricing situations that reach headline and/or US congressional visibility, a tweak to the importation debate might offer a response.
You may also be interested in...
There are rumblings a drug importation proposal is coming, but there are no signs that the HHS/FDA working group has been active in the year since it was created.
The idea of permitting importation of competitors to products like Daraprim has an undeniable appeal, and – unlike essentially every other idea on the table to deal with drug pricing – would actually address the singular example that helped kick off the current debate. But creating a legal framework to justify the action is very perilous for the industry overall.
Non-profit probably won’t ever be significant threat to industry – but frustration with chronic shortages could prompt policy changes that are.